IMVT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Immunovant Inc (IMVT) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock shows potential catalysts such as upcoming Phase 3 trial results and strong hedge fund interest, the technical indicators suggest a bearish trend with oversold conditions, and the financial performance remains weak with negative net income and declining EPS. The lack of recent Intellectia Proprietary Trading Signals further supports a cautious stance.
The stock is currently in a bearish trend. The MACD histogram is negative (-0.255) and expanding downward, indicating bearish momentum. RSI is at 18.19, signaling oversold conditions. The stock is trading near its S1 support level of 25.066, with resistance levels at 26.468 and 27.87. Converging moving averages suggest indecision in the market.
Hedge fund buying activity has increased by 133.13% over the last quarter, indicating institutional confidence.
Upcoming topline data from two Phase 3 studies for batoclimab in the first half of the year could act as a major catalyst.
Analysts from Guggenheim have raised the price target to $44, maintaining a Buy rating.
Alpine Global Management recently sold 127,039 shares, reflecting a potential shift in confidence.
The company reported a negative net income of -$110.6M in Q3 2026, with EPS declining by 19.74% YoY.
The MACD and RSI indicate bearish momentum and oversold conditions, suggesting short-term weakness.
In Q3 2026, the company reported no revenue growth (0% YoY) and a net income of -$110.6M, down 0.44% YoY. EPS dropped significantly by 19.74% YoY to -0.61, reflecting ongoing financial struggles. Gross margin remains at 0%.
Analyst sentiment is mixed. Guggenheim raised the price target to $44 and maintains a Buy rating, while Truist raised the target to $23 but keeps a Hold rating. Wolfe Research upgraded the stock to Outperform in January 2026. Recent price target adjustments reflect cautious optimism, but the stock remains speculative due to financial challenges.
